Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fábio Cardoso Borges

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Plos One|October 8, 2021
Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal-Results from a population-based cancer registry cohort studyFábio Cardoso Borges, Adriana Ramos, António Lourenço, et al.
Scientific Reports|April 6, 2023
Epidemiological and clinical characterization of a population-based cohort of cutaneous malignant melanoma patients in the South Region of PortugalFilipa Alves da Costa, Adriana Ramos, Catarina Bernardo, et al.
Frontiers in Medicine|August 29, 2022
A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020Maria Manuel Teixeira, Fábio Cardoso Borges, Paula Sousa Ferreira, et al.
Frontiers in Medicine|August 6, 2019
Intensive Monitoring Studies for Assessing Medicines: A Systematic ReviewCarla Torre, Maria Cary, Fábio Cardoso Borges, et al.
International Journal of Clinical Pharmacy|June 4, 2018
Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanomaJoão P Aguiar, Fábio Cardoso Borges, Rodrigo Murteira, et al.
Pharmacoepidemiology and Drug Safety|August 27, 2020
Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort studyRodrigo Murteira, Fábio Cardoso Borges, Gonçalo Pinto Mendes, et al.
Breast (Edinburgh, Scotland)|February 19, 2022
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort studyFábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 17, 2025
Synergizing Needs Assessments and Patient Preference Studies for Enhanced Patient-centred Decision-Making in HealthcareElise Schoefs, Alice Vanneste, Alessandra Blonda, et al.
Breast Cancer Research : BCR|June 29, 2023
Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practiceFilipa Alves da Costa, Fábio Cardoso Borges, Adriana Ramos, et al.
Journal of Cancer Policy|January 9, 2026
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines ForumDenis Lacombe, Fábio Cardoso Borges, Ana E Amariutei, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Plos One|October 8, 2021
Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal-Results from a population-based cancer registry cohort studyFábio Cardoso Borges, Adriana Ramos, António Lourenço, et al.
Scientific Reports|April 6, 2023
Epidemiological and clinical characterization of a population-based cohort of cutaneous malignant melanoma patients in the South Region of PortugalFilipa Alves da Costa, Adriana Ramos, Catarina Bernardo, et al.
Frontiers in Medicine|August 29, 2022
A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020Maria Manuel Teixeira, Fábio Cardoso Borges, Paula Sousa Ferreira, et al.
Frontiers in Medicine|August 6, 2019
Intensive Monitoring Studies for Assessing Medicines: A Systematic ReviewCarla Torre, Maria Cary, Fábio Cardoso Borges, et al.
International Journal of Clinical Pharmacy|June 4, 2018
Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanomaJoão P Aguiar, Fábio Cardoso Borges, Rodrigo Murteira, et al.
Pharmacoepidemiology and Drug Safety|August 27, 2020
Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort studyRodrigo Murteira, Fábio Cardoso Borges, Gonçalo Pinto Mendes, et al.
Breast (Edinburgh, Scotland)|February 19, 2022
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort studyFábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 17, 2025
Synergizing Needs Assessments and Patient Preference Studies for Enhanced Patient-centred Decision-Making in HealthcareElise Schoefs, Alice Vanneste, Alessandra Blonda, et al.
Breast Cancer Research : BCR|June 29, 2023
Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practiceFilipa Alves da Costa, Fábio Cardoso Borges, Adriana Ramos, et al.
Journal of Cancer Policy|January 9, 2026
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines ForumDenis Lacombe, Fábio Cardoso Borges, Ana E Amariutei, et al.
Pageof 2